Goodwin Biotechnology Inc. Completes cGMP Manufacturing of AREVA Med LLC's Conjugate

Published: Sep 14, 2009

PLANTATION, Fla., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) announced today the completion of the cGMP manufacturing and vialing of AREVA Med's monoclonal antibody-chelator conjugate. As part of AREVA Med's Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical trials to treat several types of deadly forms of cancers. AREVA Med will benefit from the vast expertise in the nuclear industry from AREVA, its parent company, that allowed for the production of this radioisotope previously considered a scarce resource.

Back to news